Rationale and Design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Amat-Santos IJ
  • Sánchez-Luna JP
  • Abu-Assi E
  • Melendo Viu M
  • Cruz-Gonzalez I
  • Nombela-Franco L
  • Muñoz García AJ
  • García Blas S
  • de la Torre Hernandez JM
  • Romaguera R
  • Sánchez-Recalde Á
  • López Otero D
  • Gheorge L
  • Ibáñez B
  • Iñiguez Romo A
  • Raposeiras-Roubín S

Grupos

Abstract

Despite aortic stenosis (AS) relief, patients undergoing transcatheter aortic valve implantation (TAVI) are at increased risk of developing heart failure (HF) within first months of intervention. Sodium-glucose co-transporter 2 (SGLT-2) inhibitors have been shown to reduce the risk of HF hospitalization in individuals with diabetes mellitus (DM), reduced left ventricular ejection fraction (LVEF) and chronic kidney disease (CKD). However, the effect of SGLT-2 inhibitors on outcomes after TAVI is unknown. The Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) trial is designed to assess the clinical benefit and safety of the SGLT-2 inhibitor dapagliflozin in patients undergoing TAVI.

© 2021 European Society of Cardiology.

Datos de la publicación

ISSN/ISSNe:
1388-9842, 1879-0844

EUROPEAN JOURNAL OF HEART FAILURE  OXFORD UNIV PRESS

Tipo:
Article
Páginas:
581-588
PubMed:
34693613
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
5,231 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 25

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Dapagliflozin, Heart Failure, Sodium-glucose co-transporter 2 inhibitor, Trial Design

Campos de Estudio

Cita

Compartir